Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06835919 Safety and PK Study
NCT03031119Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06835919 in Nonalcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) (3 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Treatment-Related Adverse Events, Number of Participants With Clinical Laboratory Abnormalities and 7 more. Started Jan 2017; status: completed.
02
Drugs
PF-06835919
03
Conditions
Nonalcoholic steatohepatitis (NASH)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03031119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03031119.